Nuvectis Pharma, Inc. filed a Form 8-K on August 21, 2026, disclosing the establishment of a new at-the-market equity offering program with Jefferies LLC as sales agent, alongside the termination of its prior ATM program.
Key Highlights
- New ATM program: Nuvectis Pharma entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026.
- Shelf registration: The company filed a new Form S-3 shelf registration statement on August 21, 2026, registering $200 million in securities.
- Agent compensation: Jefferies will receive up to 3.0% of gross proceeds from any ATM shares sold under the agreement.
- No minimum sales obligation: Jefferies is not required to sell any specific number or dollar amount of securities.
- Prior ATM terminated: The company terminated its prior at-the-market program on July 20, 2026, originally filed with the SEC on February 13, 2026 under Registration Statement File No. 333-293459.
- Common stock par value: Shares offered are common stock with a par value of $0.00001 per share.
Nuvectis Pharma Replaces Prior ATM with New $200 Million Shelf-Backed Program
According to the filing, Nuvectis Pharma, Inc. (NASDAQ:NVCT) entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026, under which the company may offer and sell shares of its common stock from time to time through Jefferies acting as sales agent. The company disclosed that it expects to file a prospectus supplement relating to the agreement under a new shelf Registration Statement on Form S-3 registering $200 million in securities, also filed on August 21, 2026.
The filing states that any sales of shares under the program will be made in transactions deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933. Jefferies will use "commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations on mutually agreed terms," according to the filing. The company noted that actual proceeds, if any, will depend on the number of shares sold and the offering price at the time of each sale. The agreement includes customary representations, warranties, indemnification rights, and obligations.
Separately, the company disclosed that it terminated its prior at-the-market offering program on July 20, 2026. That prior program had been conducted pursuant to a prospectus supplement filed with the SEC on February 13, 2026, as part of Registration Statement on Form S-3 with File No. 333-293459. The filing states that "no further offerings or sales of Common Stock will be conducted under the Prior ATM or the Prior Prospectus Supplement." The 8-K was signed by Ron Bentsur, Chairman, Chief Executive Officer and President.
What Was Disclosed
Nuvectis Pharma disclosed the launch of a new at-the-market equity offering program backed by a $200 million shelf registration, with Jefferies LLC as sales agent at up to 3.0% commission on gross proceeds, and the concurrent termination of its prior ATM program effective July 20, 2026.




Please wait processing your request...